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India  accounts  for 23%  of global  rotavirus  mortality  in under-ﬁve  children,  with  more  than  100,000  deaths
from rotavirus  annually.  Introduction  of  a vaccine  in  India is considered  to be  the  most  effective  inter-
vention  for  preventing  rotavirus  mortality.  Recent  research  suggests  that  there  is considerable  variation
in  rotavirus  mortality  burden  across  regional,  gender  and  socio-economic  subpopulations  within  India.
In addition,  there  is  potential  variability  in who  would  likely  receive  rotavirus  vaccine  if introduced.  We
use  available  household  data  to estimate  heterogeneity  in  rotavirus  mortality  risk, vaccination  beneﬁts,
and cost-effectiveness  across  geographic  and  socio-economic  groups  within  India.  We  account  for  het-
erogeneity  by  modeling  estimated  three-dose  routine  vaccinations  as  a proxy  for  a  generalized  rotavirus
vaccine,  and  mortality  for subpopulations  of children  aggregated  by  region  and state,  socio-economic
status  and  sex,  separately.  Results  are  presented  for  six  geographic  regions  and  for  Bihar,  Uttar  Pradesh,
and Madhya  Pradesh,  three  high  mortality  states  accounting  for 56%  of national  mortality  estimates.
Impact  estimates  accounting  for disparities  predict  rotavirus  vaccine  introduction  will  prevent  35,000
deaths  at  an  average  cost  of  $118/DALY  averted  (7292  INR/DALY  averted).  Rotavirus  vaccines  are  most
cost-effective  for  the  poor  living  in high  mortality  regions  and  states.  Reductions  in geographic  and  socio-
economic  disparities  based  on regional  estimates  could  prevent  an additional  9400  deaths  annually,  while
reductions  in socio-economic  disparities  in the  three  highest  morality  states  alone  could  prevent  an  addi-
tional 10,600  deaths  annually.  Understanding  the  impact  of heterogeneity  can help  improve  strategies
to  maximize  the beneﬁts  of  rotavirus  vaccination  introduction,  leading  to fewer  lives  lost  as  a result  of
rotavirus  disease.
©  2014  Published  by Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Diarrheal deaths are the second leading cause of child mortality
ccounting for 15% of the global under-ﬁve child mortality burden
1]. It is estimated that 39% of these diarrheal deaths, which occur
ainly in middle and low income countries, are due to rotavirus
∗ Corresponding author at: Department of Environmental and Global Health, Cen-
er  for African Studies, Emerging Pathogens Institute, University of Florida, Box
00188, 101 S. Newell Dr, Room 2148, Gainesville, FL 32610, USA.
el.: +1 352 294 5110; fax: +1 352 273 6070.
E-mail addresses: rrheing@epi.uﬂ.edu, rrheing@uﬂ.edu (R. Rheingans),
5anders@epi.uﬂ.edu (J.D. Anderson IV), ander88@epi.uﬂ.edu
B. Anderson), poulomyc@epi.uﬂ.edu (P. Chakraborty), datherly@path.org
D. Atherly), dpindolia@gmail.com (D. Pindolia).
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.073
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC infection [2]. Realizing the pressing need to prevent childhood
diarrheal mortality and morbidity, WHO  recommended the intro-
duction of rotavirus vaccines in countries with high population
vulnerability, including India [3]. India alone accounts for 23% of
global rotavirus mortality, with 100,000 rotavirus deaths annu-
ally [4]. Apart from improvements in water, sanitation, nutrition
and public health conditions, introduction of a vaccine in India is
considered to be the most effective intervention [5,6].
Development of rotavirus vaccines shows potential for signiﬁ-
cantly reducing rotavirus burden. Initial estimates of health impact
and cost-effectiveness of rotavirus vaccine introduction in India
showed the vaccine to be cost effective [5,7–9] and protective [10].
However, decisions regarding nation-wide introduction require the
best and most recent data on disease burden, vaccine delivery, costs
and effectiveness [11,12]. Geographic differences in burden require
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ngoing surveillance to maximize vaccine effectiveness [13] and
ill be especially important in India.
Recent research suggests that the burden of rotavirus mortal-
ty within India differs across states and regions [14]. At the state
evel, the highest rates of rotavirus mortality are found in Bihar,
ttar Pradesh and Madhya Pradesh, jointly accounting for more
han half of rotavirus deaths in India. Regionally, rotavirus deaths
re highest in central India, followed by northern, while lowest in
estern India. In addition to regional heterogeneity, rotavirus mor-
ality rates amongst girls (4.89 deaths/1000 live births) in India are
ound to be 42% higher than amongst boys (3.45 deaths/1000 live
irths) [14]. Socio-economic differences play a role as well. Known
ndividual risk factors associated with diarrheal mortality such as
eing undernourished [15] and scoring low on composite measures
f anthropometric failures occur more often in poor households in
ndia [16].
Past research in India has revealed regional, socio-economic and
ender disparities in routine immunization rates [17,18]. Socio-
conomic disparities in burden are found to correspond with
isparities in access to routine vaccination, with children belonging
o the poorest households having the highest rotavirus deaths and
he lowest estimated vaccination rates [7]. Gender-based dispari-
ies in rates of childhood immunization have been shown as well;
irls are reported to have lower vaccination rates than boys and,
imilar to rotavirus mortality, there is signiﬁcant variation across
tates and regions [19,20]. Moreover, girls at higher birth orders are
ound to have a greater chance of missing vaccination doses, than
oys [21]. These disparities, left unchanged, reduce the potential
mpact and cost-effectiveness of rotavirus vaccination [7].
The purpose of this study is to use the best available data on
otavirus mortality, health care cost, vaccine access, and efﬁcacy to
stimate the impact and cost-effectiveness of rotavirus vaccination
cross different geographic and socio-economic settings in India.
e  also examine alternative strategies for increasing the impact of
accine introduction.
. Materials and methods
.1. Overview
We  use a spreadsheet-based model developed in Microsoft Excel
22] to estimate the expected health and economic outcomes for
ne annual birth cohort of children during the ﬁrst 5 years of life.
ue to the known heterogeneity by geography, socio-economic
evel and gender, we  model a series of sub-populations sepa-
ately. Speciﬁcally, we consider six geographic regions (based on
orris et al. [14]), together representing all of India, separately,
nd independently calculate results for three high mortality states
Bihar, Uttar Pradesh, and Madhya Pradesh). Within each geo-
raphic area we group children into ﬁve wealth quintiles based
n asset index [23]. As a result, the modeling unit of analysis is
eographic area × wealth quintile × sex.
Future outcomes are discounted at 3% and costs are estimated
n 2013 US dollars.
.2. Burden of rotavirus mortality
Overall estimates of rotavirus mortality by region, state and sex
re taken from Morris et al. [14] (Table 1). However it is likely
hat there is substantial heterogeneity in rotavirus mortality risk
ithin these groups due to differential nutritional status and accesso basic care for diarrheal disease, based on socio-economic sta-
us. As a result, we developed an evidence-based individual risk
ndex to estimate the relative distribution of mortality within these
egion-sex populations.2S (2014) A140–A150 A141
We used data from the 2005 to 2006 India National Family
Health Survey III (NFHS-3) [24] to calculate individual risk index
values as well as mean values for each subpopulation, account-
ing for complex survey design in Stata (version 12) [25]. The risk
index assumes that an individual child’s risk of rotavirus mor-
tality is a function of the child’s nutritional status (as measured
by weight-for-age) and the likelihood of receiving rehydration if
he/she experiences a diarrheal event. The existing literature sug-
gests that both factors are strongly and quantitatively linked to
diarrheal mortality (although not speciﬁcally rotavirus mortality)
[15,26]. A nutritional risk factor was developed for each child based
on their weight for age and a linearized estimate of relative risk
from Caulﬁeld et al. [15] (WFAi). Since data on rehydration is only
available for children with an episode of diarrhea in the previous 2
weeks we  estimated the individual propensity for receiving rehy-
dration by ﬁtting a logistic regression model to predict rehydration
based on age, asset index score, gender and state. We  then used
the PREDICT function in Stata (version 12) [25] to estimate the
propensity for all children (PrORSi). The individual risk factor for
rehydration was calculated for each child as the product of their
propensity score and 0.07 (ˇORS), based on the estimated 93% effec-
tiveness of appropriate rehydration from Munos et al. [26]. For each
region (r) wealth quintile (q) and sex (s) sub-population, the mean
risk index was calculated based on Equation (1).
RVRiskIndexr,q,s =
∑Nr,q,s
i
ˇORS · PrORSi · WFAi
Nr,q,s
(1)
In order to test this individual risk model, we  examined the
correlation between state-wide averages generated as described
above, with the statewide mortality estimates from Morris et al.
[14].
In order to estimate the distribution of rotavirus mortality
within geographic-economic-gender subpopulations we combined
the risk index and the mortality estimates by geographic area and
gender from Morris et al. [14]. The risk index for each wealth quin-
tile was normalized by dividing by the mean risk index for the
corresponding geographic area and gender subpopulation (Equa-
tion (2)). This ensures that the total mortality for any geographic
area and gender is the same as Morris et al. [14], while maintaining
an estimated distribution across wealth quintiles based on individ-
ual risk factors and quantitative relative risk estimates from the
literature. Rotavirus mortality burden is estimated as deaths per
1000 live births.
RVBurdenr,q,s =
RVMortr,s · RVRiskIndexr,q,s
RVRiskIndexr,s
(2)
All subpopulation means were calculated using appropriate
sample weights based on the design of each survey.
Mortality risk was  converted into Disability Adjusted Life Years
(DALYs) based on standard methods using age weighting and dis-
counting [27,28]. Previous studies have shown that over 98% of
DALYs associated with rotavirus diarrhea in low income settings are
associated with mortality [29,30], as a result we have not estimated
DALYs associated with morbidity from acute cases.
We estimated timing of projected deaths by combining overall
rotavirus mortality estimates for each subpopulation and the esti-
mated age distribution of events from Morris et al. [14], combined
with additional data from Clark and Sanderson [31,32]. Monthly
rates were estimated for the ﬁrst year of life, and annually for
the subsequent 4 years of life. For any subpopulation and period
t, mortality burden is estimated in Equation (3), as:
RVBurdenr,q,s,t = RVTimet · RVBurdenr,q,s (3)where RVTimet is the fraction of deaths occurring in time period t.
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Table 1
Input values, ranges, and references for variables used in the analysis.
Input Value** Range Reference
Rotavirus mortality Deaths
National rotavirus mortality rate among
children under 5 (deaths/1000 live births)
4.1 3.1–5.7 99% CI; lognormal distribution [14]
Regional and state rotavirus mortality rate Various Lognormal distribution with 99% CI
proportional to national estimate
[14]
Risk factors for mortality by sub-group† [24]
RV vaccine – efﬁcacy
Full course (three doses) – 1st year 50% 40–60%; triangular [8,47]
2 Dose – 1st year 25% 15–35%; triangular Assumption
1  Dose – 1st year 10% 0–20%; triangular Assumption
Full  course (three doses) – Year 2 and later 45% 35–55%; triangular
2  Dose – Year 2 and later 25% 15–35%; triangular
1  Dose – Year 2 and later 10% 0–20%; triangular
Vaccination
1,  2, and 3 dose coverage (by sub-group) Various [34]
Vaccination timing (by sub-group) Various [33]
Medical costs
Mean medical cost per child (US$) $2.50 $1.25–3.75; triangular [40,41]
Healthcare utilization by sub-group [24]
Pharmacy $0.47 [42]
Healer $0.47 [42]
Public (in/out patient) $1.81 [40,41]
Private out patient $3.04 [41]
Private in patient $74.98 [40]
Vaccine costs
Dose (US$) $1.25 $0.50–$1.50; triangular Assumption
Administration (US$) $1.25 $0.50–$1.50; triangular [8]
†
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aNFHS risk factor index sample size (range across regions) = 8263 1-year-olds; 4363
** 1 2013 US$ = 61.8 2013 Indian rupees (INR).
.3. Vaccination coverage and effectiveness
We  estimated the coverage of a ‘generalized’ 3-dose rotavirus
accine that would be delivered alongside DPT1–3 through a rou-
ine immunization program. Vaccine effectiveness was estimated
or each subpopulation based on estimated coverage of each of
hree doses, the expected timing of receiving each dose, and
xpected efﬁcacy of each dose over time.
Vaccination coverage was estimated by geographic area, gender
nd wealth quintile. Due to concerted national and state efforts,
overage of routine vaccinations in India is rapidly improving. We
sed three alternative sources to estimate coverage: 2005–2006
FHS-3 [24], 2007–2008 District Level Health Survey (DLHS-3) [33],
nd the 2009 Coverage Evaluation Survey (CES) [34]. A fourth sur-
ey, the Annual Health Survey [35–37], was also consulted but it
oes not provide national estimates and was used descriptively.
or the NFHS and the DLHS3, we estimate coverage of DPT1, DPT2
nd DPT3 for each geographic area r, sex s and wealth quintile q
ub-population.
Vaccination timing was  estimated for all three doses using vac-
ination data for 1-year-olds from DLHS-3. Speciﬁcally, for each
ubpopulation we estimated the proportion of children receiving
ach dose by the end of each time period t. For any subpopula-
ion, the coverage for each dose d was deﬁned in equation (4) as
he product coverage and the likelihood of receiving it by a given
eriod t.
ovd,r,q,s,t = Dosed,r,q,s · Timed,r,q,s,t (4)
This model is intended to be generalized, rather than pertaining
o a single particular vaccine. As a result, we assumed efﬁcacy that
s similar to recent published estimates [10] and assumed the same
fﬁcacy in each subgroup. Vaccine efﬁcacy was estimated for 1, 2,
nd 3 doses to account for incomplete courses and rotavirus events
hat might occur between doses. During the ﬁrst year we assumed
n efﬁcacy of 50% for a full course, and 10% and 25% efﬁcacy for 1
nd 2 doses [5,38]. We  also assumed a 10% waning in efﬁcacy (to (503–1126) and 3900 girls (430–1017).
45%) during subsequent years [39]. Full assumptions are shown in
Table 1.
Vaccination effectiveness and beneﬁt were estimated for each
subpopulation by combining information on the coverage and efﬁ-
cacy of each dose by time period with information on the expected
burden over time.
VacBenefitr,q,s =
∑
d,t
Covd,r,q,s,t · VacEffd,t · RVBurderr,q,s,t (5)
where VacEffd,t is the incremental protection of each dose d during
time period t.
The method described above accounts for the correlation
between individual risk and vaccine access at the region-quintile-
sex sub-group level, however it implicitly assumes that risk and
access are not correlated within each subgroup. We  tested this
assumption by examining the correlation of DTP2 coverage and risk
index within each subgroup.
Estimating the expected beneﬁts at current coverage levels, we
also estimated the potential beneﬁts if all geographic-economic
sub-groups had the same mortality reduction as the highest cov-
erage group (South, middle quintile, 40%). The difference between
these potential beneﬁts and expected beneﬁts were deﬁned as the
health consequence of coverage disparities.
2.4. Economic outcomes
Patterns of healthcare utilization for diarrheal treatment vary
geographically and by socio-economic status. As a result, direct
medical costs for rotavirus treatment are expected to vary as well.
However, limited data are currently available on the extent of
variability. In order to account for this heterogeneity in cost we
combined published estimates of overall rotavirus direct medical
costs [40,41] per child with an estimate of the relative cost per child
in each geographic and economic setting [42] (Table 1).
We  estimated the distribution of costs among children based
on the pattern of care seeking (NFHS-3) weighted by estimated
cost of each treatment type (Table 2). While consistent data are
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Table 2
Distribution of treatment sought for diarrheal episodes for children 12–23 months of age by wealth status, setting and region.
Wealth quintiles Setting Region
Poorest Second Middle Fourth Richest Urban Rural North Central East Northeast West South
Treatment % (SE)
None 33.0 (4.5) 29.5 (3.7) 24.8 (3.8) 19.1 (3.5) 15.3 (3.7) 22.7 (2.8) 26.8 (1.9) 19.5 (3.4) 25.4 (2.7) 25.2 (3.7) 46.9 (4.6) 22.8 (3.7) 29.4 (4.2)
Public  inpatient
Hospital 3.6 (1.6) 3.0 (1.4) 9.3 (2.4) 6.6 (1.6) 5.1 (2.2) 10.2 (1.8) 3.4 (0.8) 5.3 (1.6) 4.2 (1.2) 3.6 (1.4) 2.6 (0.8) 4.7 (1.7) 13.2 (3.1)
UHC  0.0 (0.0) – – – – – – – – – – – –
CHC  9.1 (2.4) 6.9 (2.0) 6.7 (2.4) 5.4 (2.0) 5.5 (2.1) 4.5 (1.3) 7.9 (1.1) 4.4 (1.3) 6.1 (1.6) 6.4 (1.5) 3.9 (1.5) 10.3 (2.9) 8.6 (2.6)
Public  outpatient
Dispensary 0.4 (0.0) 0.4 (0.4) 0.8 (0.4) 1.8 (0.5) 1.0 (0.5) 1.3 (0.4) 0.6 (0.2) 8.6 (2.0) – 0.1 (0.1) 3.7 (2.4) – 0.8 (0.8)
Mobile  clinic – 0.7 (0.8) – 0.8 (0.9) – – 0.4 (0.3) – 0.4 (0.4) – – 0.9 (0.9) –
ASHA  – – – – – – – – – – – – –
Sub-centre  2.1 (1.2) 3.0 (1.5) 1.4 (1.1) 0.2 (0.2) – – 2.1 (0.6) – 2.6 (0.9) 1.2 (0.8) 1.7 (1.0) 1.6 (1.1) –
Camp  – 0.0 (0.0) 0.1 (0.1) – – 0.1 (0.1) 0.0 (0.0) 0.2 (0.2) – – 0.2 (0.2) – –
Anganwadi 1.9 (1.3) 1.3 (0.9) – 0.8 (0.7) – – 1.3 (0.5) – 0.3 (0.3) 2.2 (1.1) 0.4 (0.4) 0.7 (0.7) 0.8 (0.8)
Other  public – 0.7 (0.8) – 0.7 (0.5) – 0.2 (0.2) 0.3 (0.2) – – 0.7 (0.6) 2.3 (2.2) – –
Private  inpatient
Hospital 3.1 (1.6) 5.0 (1.5) 9.2 (2.8) 14.4 (3.0) 28.6 (4.2) 18.1 (2.6) 7.5 (1.1) 16.2 (3.0) 4.9 (1.2) 4.3 (1.7) 3.1 (1.4) 17.5 (3.4) 29.1 (4.6)
NGO  Hospital/Clinic 0.0 (0.0) 0.5 (0.6) – – – 0.0 (0.0) 0.2 (0.2) – – – 0.3 (0.2) 0.7 (0.7) –
Private  outpatient
Doctor/Clinic 31.8 (5.1) 31.2 (3.9) 34.2 (4.7) 39.5 (4.6) 41.9 (5.2) 35.4 (3.0) 34.8 (2.3) 35.1 (4.1) 42.3 (3.1) 32.0 (4.7) 11.2 (3.4) 38.0 (4.4) 22.4 (3.8)
Paramedic 0.7 (0.8) 0.2 (0.3) 0.6 (0.4) 0.9 (0.5) 0.4 (0.5) 0.2 (0.2) 0.7 (0.3) 5.2 (1.9) 0.6 (0.4) 0.2 (0.2) 0.1 (0.1) – –
Homeopathic 1.3 (1.3) 1.5 (1.0) 1.4 (1.2) 0.7 (0.6) 1.3 (1.1) 1.0 (0.6) 1.4 (0.5) 1.3 (0.9) 0.7 (0.5) 2.8 (1.3) 5.2 (3.1) – –
Private  other 7.8 (2.5) 10.6 (2.7) 7.9 (2.8) – 0.1 (0.2) 0.1 (0.1) 8.2 (1.3) 0.3 (0.3) 4.4 (1.2) 16.2 (3.3) 0.3 (0.2) – –
Pharmacy
Pharmacy/store 0.7 (0.7) 3.6 (2.0) 2.1 (1.5) 2.3 (1.5) 0.9 (1.1) 0.9 (0.7) 2.3 (0.8) 0.9 (0.9) 2.4 (1.0) 2.1 (1.3) – 2.5 (2.0) 0.7 (0.7)
Shop  6.0 (2.5) 3.5 (1.3) 4.7 (1.7) 7.4 (2.5) 3.0 (1.6) 7.1 (1.4) 4.2 (0.9) 4.3 (1.7) 6.7 (1.4) 6.2 (1.9) 18.4 (4.7) 0.7 (0.7) –
Healer
Traditional  healer 1.1 (0.8) 0.6 (0.7) 1.0 (0.8) – – – 0.8 (0.3) – 0.9 (0.6) 0.3 (0.3) – 0.7 (0.7) 0.7 (0.7)
Children  (N) 244 256 274 288 239 481 820 188 335 232 238 165 143
A ccine 32S (2014) A140–A150
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ot available for all of these categories we estimated the relative
osts based on available published data (Table 1) and applied cost
stimates to reported categories of treatment facility or provider
n NFHS-3. Relative costs were then rescaled to have a mean of 1
nd multiplied by the average cost per child from the literature (to
nsure the same mean cost per child). Costs were estimated as a
inear function of region, urban/rural, and wealth index, imputed
or all children without data using the PREDICT function in STATA
2. The relative cost measure was then applied to the estimated
ational mean direct medical cost of rotavirus [41] to calculate a
ean rotavirus cost by geographic and socio-economic setting.
Averted medical costs (AvertCostr,q,s) were then estimated for
ach subpopulation by combining information on the coverage
nd efﬁcacy of each dose by time period with information on the
xpected medical cost over time. All costs were adjusted to 2013
S$ (1US$ = 61.8 Indian rupees, INR).
vertCostq,r,s =
∑
d,t
Covd,r,q,s,t · VacEffd,t · MedCostq,r,s,t (6)
The incremental cost of the intervention (IntCostq,r,g) includes
accine and administration costs. Intervention costs were esti-
ated assuming a baseline vaccine price of $1.25 (77.3 INR) per
ose, wastage of 10% and an incremental administration cost of
1.25 per dose [8]. The cost parameters were varied in the sensitiv-
ty analysis (Table 1).
The main outcome measure was the incremental cost-
ffectiveness ratio (ICERq,r), which was estimated for each
eographic and economic subpopulation.
CERq,r,s =
IntCost − AvertCostq,r,s
VacBenefitq,r,s
(7)
.5. Sensitivity and uncertainty analysis
A series of analyses were conducted to assess the impact of
ncertainty to predicted outcomes. One-way sensitivity analyses
ere used to estimate the effect of changes in individual input
ariables (ranges listed in Table 1). A probabilistic sensitivity anal-
sis (PSA) using Monte Carlo analysis was used to assess the effect
f simultaneous changes in multiple input variables. Key input
ariables were characterized as distributions (Table 1) and a simu-
ation procedure using 10,000 iterations was conducted in Crystal
all [43] to develop a distribution of estimated impact and cost-
ffectiveness by region. Lastly, speciﬁc scenarios were examined
ncluding on-time vaccination, equitable coverage, and full cover-
ge.
In addition, we developed an “Equal risk” scenario where we
ssumed homogeneous RV mortality risk and treatment costs. We
sed this scenario to approximate the estimated beneﬁts and cost-
ffectiveness ratio if inter and intra region disparities were not
onsidered.
. Results
.1. Health and medical cost burden by setting
Estimated mortality and direct medical costs are shown for each
egion-quintile sub-group (Fig. 1a) and state-quintile sub-group
Fig. 1b). In the ﬁgures, each line represents a different region or
tate and each of the dots represent different wealth quintiles.
ifference in mortality among regions reﬂects the differences esti-
ated by Morris and colleagues [14]. Within all of the regions,hildren in poorer households had higher risk of mortality, due to
educed nutritional status and reduced likelihood of receiving rehy-
ration. Conversely, within all regions children in richer households
ad a higher estimated direct medical cost burden (Fig. 1a and b).Fig. 1. a–b – Estimated direct medical costs and rotavirus mortality risk by geogra-
phy and wealth quintile in India (MP  = Madhya Pradesh, and UP  = Uttar Pradesh).
This difference is driven by an increased likelihood of treatment
and in particular increased utilization of private hospitals (Table 2).
These differences were observed across the three high mortality
states as well.
3.2. Impact of vaccination
We  estimate that vaccine introduction will reduce rotavirus
disease burden by 30% to 39% depending on the region, with the
greatest percent reduction estimated in the South (39%), followed
by the North (34%) and West regions (34%), Table 3. The absolute
level of beneﬁts (deaths averted per 1000 births) also varied across
regions, ranging from 0.55 to 1.66 rotavirus deaths per 1000 births,
with the highest beneﬁts estimated in Central, Northeast, and East
regions.
Impact varied substantially within regions as well. Fig. 2 shows
the estimated effectiveness by geographical region and economic
status. For all regions, the highest percent reduction in burden was
estimated for the two  highest wealth quintiles. The highest and
most equitable reduction was estimated in the South, ranging from
38% to 40% across quintiles. Children in poorer households experi-
enced higher mortality risk and lower levels of mortality reduction,
particularly in the Central, East and Northeast regions. Estimated
average risk for the poor in these three regions is 1.7 times higher
with average mortality reductions of 28% as compared to 33% in
other regions, respectively.
The estimated health beneﬁts with current coverage and poten-
tial coverage are shown in Fig. 3. The highest potential additional
beneﬁts are among the high mortality regions and states, and
particularly among the poorest quintiles. Nationally, increased cov-
erage would increase beneﬁt estimates by 23%, preventing 9400
additional deaths. In Bihar, Madhya Pradesh and Uttar Pradesh ben-
eﬁt estimates would increase by 55%, 76% and 71%, respectively,
preventing 10,600 additional deaths. Among the poorest quintile
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Table 3
Estimated impact, costs, and cost-effectiveness of rotavirus vaccination for regions and selected states in India based on data from CES 2009a.
Burden (RV
deaths/1000
births)
Beneﬁts (RV deaths
averted/1000
births)
% Reduction Costs averted
($/1000 births)
Vaccination costs
($/1000 births)
CER ($/DALY
averted)
Equal risk beneﬁts (RV
deaths averted/1000
births)
Equal risk CER
($/DALY
averted)
National 3.71 1.22 33.7 1089 6821 139 1.40 124
Region
Central  5.49 (4.45, 6.83) 1.66 (1.32, 2.10) 30.3 (27.0, 33.0) 418 (248, 591) 6367 (3343, 11152) 105 (50, 199) 1.28 129
East  4.66 (3.78, 5.81) 1.40 (1.11, 1.77) 30.0 (27.0, 33.0) 462 (274, 657) 6340 (3336, 10995) 124 (58, 236) 1.28 128
North  3.23 (2.63, 4.01) 1.11 (0.88, 1.40) 34.2 (31.0, 37.0) 1304 (781, 1852) 6841 (3610, 11659) 147 (58, 291) 1.47 120
Northeast 4.82 (3.92, 6.01) 1.54 (1.23, 1.95) 32.0 (29.0, 35.0) 345 (205, 485) 6552 (3451, 11455) 118 (57, 223) 1.36 124
South  2.50 (2.03, 3.11) 0.97 (0.77, 1.22) 38.6 (35.0, 42.0) 2233 (1349, 3169) 7491 (3895, 12947) 160 (46, 349) 1.60 120
West  1.64 (1.33, 2.04) 0.55 (0.44, 0.69) 33.5 (30.0, 36.0) 1372 (811, 1937) 6937 (3655, 11941) 298 (117, 600) 1.44 124
State
Bihar  6.30 (5.12, 7.81) 1.62 (1.29, 2.04) 25.7 (24.0, 28.0) 398 (236, 564) 5648 (2948, 9812) 95 (44, 181) 1.10 134
Madhya Pradesh 6.20 (4.38, 6.72) 1.44 (0.96, 1.53) 23.3 (20.0, 24.0) 388 (180, 425) 5253 (2573, 8278) 99 (53, 206) 0.97 129
Uttar  Pradesh 5.40 (5.02, 7.77) 1.21 (1.14, 1.81) 22.5 (21.0, 25.0) 301 (232, 548) 4825 (2772, 9120) 110 (47, 189) 1.02 134
a Lower (5%) and upper (95%) bound estimates from the probabilistic sensitivity analysis in parentheses following means.
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0%  effectiveness, see Fig. 2).
uggesting that rotavirus vaccines with the modeled characteristics
ould be highly cost-effective.
.4. Sensitivity and uncertainty analysis
One-way sensitivity analysis was conducted to examine the
ffects of speciﬁc input variables on vaccination beneﬁt and cost-
ffectiveness within each geographic area. The results for the
mpact on the cost-effectiveness ratio are shown in Fig. 4. For
ll regions, the variables with the greatest impact were vaccine
dministration cost, rotavirus mortality, and vaccine price, usu-
lly in that order. Mortality uncertainty was most important in
igher mortality regions. Other variables had limited impact. The
ensitivity analysis for vaccination beneﬁt showed that rotavirus
ortality accounted for the greatest uncertainty in impact (results
ot shown). We  also examined the effects of speciﬁc scenarios on
ER: on-time delivery of vaccine doses and uniform medical costs.
n-time delivery reduced the CER in all regions (between 3 andphy and wealth (MP  = Madhya Pradesh and UP = Uttar Pradesh). Additional potential
ame estimated vaccine effectiveness as the highest quintile (South, middle quintile:
12 $/DALY averted, 185 and 742 INR/DALY averted). Assuming uni-
form medical treatment costs, resulted in increased CER in regions
with higher healthcare utilization and decreased the CER in regions
with low utilization.
The probabilistic sensitivity analysis was used to estimate
uncertainty limits around key outcome variables within each geo-
graphic region. These are shown in Table 1. A contribution to
variance analysis demonstrated that vaccination administration
costs and rotavirus mortality uncertainty contributed approxi-
mately 50% and 25% respectively to the overall uncertainty of the
CER, and rotavirus mortality contributed over 80% of the overall
uncertainty of the health impact of vaccination.
The effect of accounting for disparities in mortality risk and
costs can be seen in the comparison to the “Equal Risk” scenario
in Table 3. Assuming equal RV mortality risks and treatment costs
would result in a 15% overestimation of beneﬁt at a national level
(1.22 vs. 1.44 deaths averted/1000 births). It also would result in an
underestimation of the beneﬁts of introducing vaccination in high
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F  (high
m
a
4
d
c
s
s
p
o
f
h
c
e
i
cig. 4. Tornado plots of one-way sensitivity analysis. Orange bars represent upside
ortality regions or states and overestimation of the CER in those
reas.
. Discussion
At a regional level, deaths due to rotavirus are expected to
ecline by 30–40% in India with the introduction of rotavirus vac-
ine. Vaccination is estimated to reduce deaths by 23–26% in the
tates with the highest rotavirus mortality. Among all regions and
tates evaluated, our current analysis suggests that a vaccination
rogram would be highly cost-effective – consistent with ﬁndings
f previous analyses [5,7–9].
The greatest potential health beneﬁts of vaccination will come
rom reaching high rotavirus mortality areas and the poorest house-
olds. However, these populations are less likely to beneﬁt given
urrent low coverage estimates. While national vaccination cov-
rage has increased over time in India, further coverage increases
n these populations could substantially expand the impact of vac-
ination. The state level analyses presented here suggest that the) estimates while blue bars represent downside (low) estimates for each variable.
greatest beneﬁts may  come from focusing on states (or smaller geo-
graphic units) with high mortality risk and low coverage of the most
vulnerable.
The relationship between healthcare access and disease risk
results in clear tradeoffs between economic and health burden
across sub-populations. Groups with higher estimated rotavirus
mortality tend to have lower healthcare costs. This is not unex-
pected given that poor access to care contributes to increased
risk of mortality (e.g. less likely to receive timely rehydration).
In addition, some of the same underlying factors such as geo-
graphic distance, lack of access to services, and low household
economic resources, can contribute to increased risk and reduced
healthcare utilization. The result is an inverse relationship between
economic and health burdens among the sub-groups, with some
showing greater health burden and others greater economic
burden.
This pattern of heterogeneity in economic and health burden
leads to alternative rationales for vaccination in different sub-
groups. In some of the highest mortality states and poorest wealth
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uintiles, the primary justiﬁcation for vaccination is the potential
eduction in diarrheal mortality. In contrast, in lower mortality
nd higher wealth groups, the primary beneﬁt is the potential
or averting costs. Of course, in a given population both eco-
omic and health beneﬁts occur, but their relative magnitudes will
ary.
The current study has several important limitations. The esti-
ates of rotavirus mortality by region are based on Morris et al.
14]. While these are the most recent published estimates by region,
he original data is approximately a decade old. Changes in under-
ying mortality may  reduce the differences observed between and
ithin regions. We  used a wide range of mortality estimates to
ddress this in our sensitivity analysis. There is also uncertainty in
ow we estimated rotavirus mortality within regions using risk fac-
ors and published risk estimates. Other risk factors not considered
ere may  increase or decrease disparities in rotavirus mortality
mong economic groups. This analysis only follows one birth cohort
nd does not account for possible changes in coverage equity in
ubsequent cohorts as suggested by Victora et al. [45]. The current
nalysis suggests that healthcare utilization patterns vary across
eographic and socio-economic groups, resulting in differences in
xpected costs and potential cost savings. Although we attempted
o account for these differences in utilization, we did not account
or potential differences in the cost associated with different levels
f care in different settings. For example, the costs of private out-
atient or inpatient care might be greater in higher income areas.
dditional data on differences in both utilization and unit costs
f treatment are needed to develop better estimates. The current
odel used a relatively crude approach to modeling waning of pro-
ection, with uniform protection during the ﬁrst year of life and
educed efﬁcacy thereafter. A more nuanced model accounting for
he timing of vaccination would provide more realistic estimates.
astly, the results demonstrate that estimated risk and vaccina-
ion are correlated across geographic and socio-economic setting
Appendix A). Further analysis shows that there are also correla-
ions between risk and access within these sub-groups. However,
Overall Poorest Poorer 
DPT dose 1  2 3 1 2 3 1  2 
National
ORS risk −0.34* −0.35* −0.35* −0.25* −0.28* −0.23* −0.31* −0.32* 
WFA  −2 sd −0.13* −0.14* −0.16* −0.12* −0.12* −0.13* −0.08* −0.11* 
WFA  −3 sd −0.13* −0.15* −0.17* −0.09* −0.11* −0.12* −0.10* −0.15* 
RV  risk index −0.25* −0.27* −0.28* −0.18* −0.20* −0.18* −0.20* −0.25* 
N  8204 1424 1458 
Central
ORS  risk −0.31* −0.32* −0.34* −0.28* −0.30* −0.20* −0.15* −0.11* 
WFA  −2 sd −0.08* −0.11* −0.12* −0.08 −0.07 −0.08 −0.06 −0.11* 
WFA  −3 sd −0.10* −0.11* −0.11* −0.06 −0.05 −0.03 −0.05 −0.12* 
RV  risk index −0.19* −0.22* −0.22* −0.16* −0.15* −0.11* −0.09 −0.17* 
N  2125 355 364 
East
ORS  risk −0.35* −0.39* −0.36* −0.30* −0.32* −0.28* −0.31* −0.38* 
WFA  −2 sd −0.11* −0.14* −0.16* −0.09 −0.11 −0.12 −0.06 −0.10 
WFA  −3 sd −0.14* −0.17* −0.19* −0.13 −0.20* −0.18* −0.09 −0.13 
RV  risk index −0.24* −0.28* −0.29* −0.19* −0.24* −0.21* −0.16* −0.23* 
N  1389 231 241 
North
ORS  risk −0.21* −0.22* −0.21* −0.19* −0.14 −0.07 −0.12 −0.08 
WFA  −2 sd −0.16* −0.15* −0.15* −0.13 −0.07 −0.08 −0.05 −0.04 
WFA  −3 sd −0.15* −0.14* −0.17* −0.11 −0.04 −0.11 −0.16 −0.17 
RV  risk index −0.22* −0.22* −0.23* −0.14 −0.08 −0.09 −0.15 −0.12 
N  1144 234 219 
Northeast
ORS  risk −0.13* −0.17* −0.15* 0.03 −0.06 −0.04 −0.22* −0.26* 
WFA  −2 sd −0.12* −0.11* −0.17* −0.01 0.10 −0.18 −0.14 −0.17 
WFA  −3 sd −0.11* −0.06 −0.13* −0.03 0.07 −0.11 −0.18 −0.09 
RV  risk index −0.19* −0.18* −0.24* −0.02 0.07 −0.17 −0.29* −0.29* 
N  1481 262 275 
West
ORS  risk −0.32* −0.33* −0.33* −0.21* −0.26* −0.34* −0.24* −0.31* 
WFA  −2 sd −0.08* −0.11* −0.11* −0.14 −0.17* −0.15 0.02 −0.01 
WFA  −3 sd −0.10* −0.14* −0.13* −0.04 −0.12 −0.08 −0.04 −0.04 
RV  risk index −0.19* −0.23* −0.21* −0.12 −0.18* −0.15 −0.07 −0.10 
N  928 165 169 2S (2014) A140–A150
the current analysis does not adjust for this fact. This correlation,
with lower coverage among higher risk children, may  result in an
overestimate of the beneﬁts of vaccination. Further analysis and
more dynamic models may  be helpful in better understanding the
degree of overestimation.
With few exceptions [46] most economic evaluations of new
vaccines do not explicitly consider heterogeneity in economic costs
or in the health beneﬁts of vaccination. Evaluations at this level
can highlight the effect that disparities may  have on the impact
of health interventions, and could eventually lead to the develop-
ment of strategies that will optimize impact. Understanding the
effects of heterogeneity could strengthen ongoing and future efforts
to improve vaccination coverage, with the aim of maximizing the
beneﬁts and improving the equity of vaccine access for rotavirus
and other vaccines in India.
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Appendix A.
Estimated correlation between DPT doses and likelihood of
receiving oral rehydration solution (ORS risk), moderate and
severe under-nutrition (−2 standard deviations weight-for-age;
WFA  −2 sd), severe under-nutrition (−3 standard deviations
weight-for-age; WFA  −3 sd), and overall rotavirus risk (RV Risk
index) calculated for the NFHS-3 (2006–2007).
Middle Richer Richest
3 1 2 3 1 2 3 1 2  3
−0.34* −0.35* −0.33* −0.32* −0.30* −0.32* −0.31* −0.26* −0.25* −0.26*
−0.12* −0.06 −0.08* −0.09* −0.08* −0.07* −0.11* −0.10* −0.12* −0.14*
−0.16* −0.04 −0.08* −0.12* −0.14* −0.11* −0.13* −0.14* −0.11* −0.10*
−0.27* −0.18* −0.20* −0.22* −0.22* −0.20* −0.23* −0.24* −0.22* −0.23*
1510 1722 2090
−0.15* −0.30* −0.27* −0.26* −0.30* −0.29* −0.30* −0.25* −0.25* −0.31*
−0.13* 0.00 0.01 0.00 −0.02 −0.02 −0.02 −0.08 −0.13* −0.14*
−0.11* 0.03 0.05 0.01 −0.12* −0.09 −0.08 −0.17* −0.14* −0.13*
−0.15* −0.06 −0.05 −0.07 −0.17* −0.14* −0.15* −0.24* −0.25* −0.25*
360 425 621
−0.43* −0.32* −0.32* −0.27* −0.30* −0.34* −0.31* −0.25* −0.24* −0.21*
−0.12 −0.04 −0.10 −0.15* 0.00 0.02 −0.02 −0.12 −0.12 −0.13
−0.17* −0.02 −0.10 −0.20* −0.13 −0.08 −0.13 −0.14 −0.10 −0.06
−0.29* −0.15* −0.21* −0.26* −0.17* −0.13 −0.15* −0.22* −0.20* −0.18*
246 279 392
−0.09 −0.08 −0.07 −0.06 −0.14 −0.26* −0.18* 0.03 0.01 0.01
0.01 −0.10 −0.04 −0.03 −0.09 −0.18* −0.14 −0.04 −0.12 −0.12
−0.20* −0.07 −0.04 −0.04 −0.01 −0.15 −0.14 0.03* 0.05* 0.00
−0.12 −0.14 −0.09 −0.07 −0.06 −0.31* −0.25* 0.00 −0.03 −0.05
225 240 226
−0.17 −0.12 −0.14* −0.14 −0.07 −0.13 −0.17* −0.09 −0.11 −0.05
−0.21 −0.13 −0.11 −0.07 0.06 −0.01 −0.06 −0.04 0.00 0.01
−0.08 −0.12 −0.09 −0.03 −0.08 −0.03 −0.24 −0.01 0.00 −0.06
−0.25 −0.21 −0.23* −0.17 0.02 −0.01 −0.18 −0.13 −0.11 −0.09
278 304 362−0.17 −0.29* −0.21 −0.18 −0.25* −0.22* −0.14 −0.09 −0.12 −0.21*
−0.02 0.07 0.06 0.12 −0.01 −0.04 −0.10 0.12* 0.04 0.03
−0.05 0.06 0.02 0.06 −0.10 −0.11 −0.12 0.04* −0.07 0.00
−0.09 −0.01 −0.04 0.07 −0.13 −0.13 −0.12 0.07 −0.06 −0.05
187 214 193
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Overall Poorest Poorer 
DPT dose 1 2 3 1 2 3 1 2 
South
ORS risk −0.10* 0.02 0.06 −0.08 −0.02 0.10 0.00 0
WFA  −2 sd −0.04 −0.01 −0.06 −0.03 −0.04 −0.05 0.01 0
WFA  −3 sd −0.03 −0.05 −0.12* 0.03 0.05 −0.10 0.00 −0
RV  risk index −0.08* −0.03 −0.09* −0.03 0.00 −0.06 0.01 −0
N  1137 177 190 
Bihar
ORS  risk −0.32* −0.37* −0.35* −0.15 −0.14 −0.18* 0.05 −0
WFA  −2 sd −0.08 −0.11* −0.17* 0.07 −0.02 −0.06 −0.02 −0
WFA  −3 sd −0.11* −0.13* −0.19* 0.03 −0.06 −0.11 −0.08 −0
RV  risk index −0.18* −0.22* −0.27* 0.03 −0.05 −0.08 −0.06 −0
N  420 70 74 
Madhya  Pradesh
ORS risk −0.26* −0.32* −0.38* −0.11 −0.21 −0.21 −0.33* −0
WFA  −2 sd −0.11* −0.11* −0.14* −0.17 −0.16 −0.12 −0.01 −0
WFA  −3 sd −0.08 −0.09 −0.07 −0.07 −0.13 −0.05 0.01 0
RV  risk index −0.17* −0.19* −0.18* −0.17 −0.15 −0.07 0.02 0
N  481 77 74 
Uttar  Pradesh
ORS risk −0.28* −0.33* −0.31* −0.04 −0.01 −0.02 −0.29* −0
WFA  −2 sd −0.12* −0.14* −0.14* −0.17* −0.22* −0.18* −0.07 −0
WFA  −3 sd −0.15* −0.16* −0.17* −0.19* −0.16* −0.14* −0.05 −0
RV  risk index −0.20* −0.22* −0.22* −0.20* −0.21* −0.16* −0.08 −0
N  1044 164 180 
are statistically signiﬁcant at a 0.05 level.
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